Enlivex Therapeutics Stock News

The stock price of Enlivex Therapeutics Ltd (NASDAQ: ENLV) increased by over 4% during intraday trading today. This is why it happened.

Enlivex Therapeutics (NASDAQ:ENLV) issued its earnings results on Sunday. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the Zacks consensus estimate of ($0.21) by $0.02, Fidelity Earnings reports. Shares of NASDAQ ENLV traded down $0.15 during mid-day trading on Tuesday, reaching $7.24. 2,089 shares of the company traded hands, compared to []

Publication follows the Israeli Ministry of Health's appointment of Prof. Mevorach as the lead investigator of a team evaluating side effects of COVID-19 vaccines

Nes-Ziona, Israel, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that

Enlivex Therapeutics (ENLV) has been struggling lately, but the selling pressure may be coming to an end soon.

Enlivex (ENLV) doses the first patient in a phase IIb study evaluating its cell therapy, Allocetra, in severe and critical COVID-19 patients with acute respiratory distress syndrome.



Nes-Ziona, Israel, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased ma

Does Enlivex Therapeutics Ltd. (ENLV) have what it takes to be a top stock pick for momentum investors?

Enlivex Therapeutics Ltd  ( NASDAQ:ENLV) is surging today, up 21.8% at $12.39 at last check, after the drug maker said Israel's health ministry allowed it to kick off a mid-stage clinical trial to t

The shares of Enlivex Therapeutics Ltd (NASDAQ: ENLV) increased by over 25% pre-market. This is why it happened.

Nes Ziona, Israel, Aug. 15, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today reported that a

Nes Ziona, Israel, Aug. 09, 2021 (GLOBE NEWSWIRE) --  Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced tha

Mr. Palash joins Enlivex from Gamida Cell, where he served as Chief Operating Officer, and previously served as Chief Operating Officer of Protalix Biotherapeutics, and as General Manager of ColBar Li

Enlivex Therapeutics Ltd. is a clinical-stage biopharmaceutical company aiming to develop immunotherapies as mono/combination treatments based on macrophage reprogramming technology.